Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy
Abstract
Radiopharmaceutical therapy is changing the standard of care in prostate cancer and other malignancies. We previously reported high CD46 expression in prostate cancer and developed an antibody–drug conjugate and immunoPET agent based on the YS5 antibody, which targets a tumor-selective CD46 epitope. Here, we present the preparation, preclinical efficacy, and toxicity evaluation of [225Ac]DOTA-YS5, a radioimmunotherapy agent based on the YS5 antibody.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 14, 2023
- Source ID
- 10.1158/1078-0432.ccr-22-3291
Entities
People
- Anil P Bidkar
- Anju Wadhwa
- Bin Liu
- Chandrashekhar Dasari
- David M Wilson
- Denis R Beckford-Vera
- Emily A. Egusa
- Emily Chan
- Henry F VanBrocklin
- Jiang He
- Jonathan Chou
- Kondapa Naidu Bobba
- Li Zhang
- Niranjan Meher
- Rahul Aggarwal
- Robert R Flavell
- Robin Peter
- Ryan Tang
- Scott Bidlingmaier
- Sinan Wang
- Suchi Dhrona
- Umama Ali
- Yang Su
- Youngho Seo
Organizations
- University of California
- University of California, San Francisco
- University of Virginia